Flublock, the first recombinant protein-based seasonal influenza vaccine, is now approved in the U.S. for adults 18-49 years old. The vaccine developed by Protein Sciences is produced without growing the influenza virus or the use of chicken eggs. This allows the vaccine to be used in people with serious egg allergies and to be produced much faster. Flublock will be available in limited supply this year. What have you recommended to your patients that are not able to get the flu vaccine to help keep them well during the flu season?

For additional information, please visit FDA